Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal enterocyte mannose residues are carbohydrate structures located on the apical surface of the intestinal epithelium, primarily as part of N-linked glycans on glycoproteins such as Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) [1][2]. These residues serve as critical docking sites for various Gram-negative pathogens, most notably Adherent-Invasive Escherichia coli (AIEC) and uropathogenic E. coli (UPEC), which express the mannose-binding adhesin FimH on their type 1 fimbriae [2][3]. The interaction between bacterial FimH and these host mannose residues facilitates bacterial colonization, biofilm formation, and subsequent invasion of the intestinal mucosa, a process heavily implicated in the pathogenesis of Crohn's disease and the maintenance of a gut reservoir for recurrent urinary tract infections [3][4]. Therapeutic strategies targeting these residues involve the administration of exogenous D-mannose or high-affinity small-molecule FimH antagonists like Sibofimloc, which act as molecular decoys [5]. By competitively binding to the bacterial FimH protein, these agents prevent the pathogens from adhering to the intestinal wall, thereby promoting their clearance from the gastrointestinal tract and reducing inflammation [1][5]. This anti-adhesive approach represents a significant non-antibiotic alternative for managing chronic inflammatory conditions and preventing infectious diseases without contributing to antimicrobial resistance [4][5]. Sources: [1] Bouckaert, J., et al. (2005). Molecular Microbiology. [2] Barnich, N., et al. (2007). Journal of Clinical Investigation. [3] Wellens, A., et al. (2008). Expert Review of Anti-infective Therapy. [4] Kranjčec, B., et al. (2014). World Journal of Urology. [5] Sivignon, A., et al. (2015). Expert Opinion on Investigational Drugs.
Competitive inhibition of bacterial FimH adhesin binding to host mannosylated receptors, preventing pathogen colonization and mucosal invasion.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal enterocyte mannose residues.